Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) Operating Expenses (2022 - 2025)

Corvus Pharmaceuticals has reported Operating Expenses over the past 4 years, most recently at $12.2 million for Q4 2025.

  • Quarterly results put Operating Expenses at $12.2 million for Q4 2025, up 50.73% from a year ago — trailing twelve months through Dec 2025 was $43.0 million (up 55.99% YoY), and the annual figure for FY2025 was $43.0 million, up 55.99%.
  • Operating Expenses for Q4 2025 was $12.2 million at Corvus Pharmaceuticals, up from $10.6 million in the prior quarter.
  • Over the last five years, Operating Expenses for CRVS hit a ceiling of $12.5 million in Q3 2022 and a floor of $5.6 million in Q3 2023.
  • Median Operating Expenses over the past 4 years was $7.1 million (2022), compared with a mean of $7.9 million.
  • Biggest five-year swings in Operating Expenses: tumbled 55.42% in 2023 and later surged 72.87% in 2025.
  • Corvus Pharmaceuticals' Operating Expenses stood at $5.7 million in 2022, then decreased by 0.26% to $5.7 million in 2023, then surged by 43.43% to $8.1 million in 2024, then surged by 50.73% to $12.2 million in 2025.
  • The last three reported values for Operating Expenses were $12.2 million (Q4 2025), $10.6 million (Q3 2025), and $10.3 million (Q2 2025) per Business Quant data.